Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors

NCT02576444 is registered in ClinicalTrials.gov with Joseph Paul Eder as lead sponsor.

NCT NCT02576444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02576444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors
Lead sponsor
Joseph Paul Eder
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2015
Completion date
November 18, 2019
Enrollment
67 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer